Breaking News, Financial News

Financial Report: Enzon 4Q

Oncaspar sales were $12.1 million in the quarter (+9%) and $50.1 million for the year (+29%). DepoCyt sales were $2.5 million (+24%) and $9.0 million for the year (+5%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Enzon 4Q Revenues: $48.4 million (+1%) 4Q Loss: $466,000 (earnings were $268,000 4Q07) FY Revenues: $196.9 million (+6%) FY Loss: $2.7 million (earnings were $83.1 million FY07) Comments: Oncaspar sales were $12.1 million in the quarter (+9%) and $50.1 million for the year (+29%). DepoCyt sales were $2.5 million (+24%) and $9.0 million for the year (+5%). Abelcet sales were $6.6 million in the quarter (-14%) and $26.9 million for the year (-7%). Royalty revenue was up 5% in the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters